Intraarterial delivery of virotherapy for glioblastoma

Visish M. Srinivasan, Frederick F. Lang, Peter Kan

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Oncolytic viruses (OVs) have been used in the treatment of cancer, in a focused manner, since the 1990s. These OVs have become popular in the treatment of several cancers but are only now gaining interest in the treatment of glioblastoma (GBM) in recent clinical trials. In this review, the authors discuss the unique applications of intraarterial (IA) delivery of OVs, starting with concepts of OV, how they apply to IA delivery, and concluding with discussion of the current ongoing trials. Several OVs have been used in the treatment of GBM, including specifically several modified adenoviruses. IA delivery of OVs has been performed in the hepatic circulation and is now being studied in the cerebral circulation to help enhance delivery and specificity. There are some interesting synergies with immunotherapy and IA delivery of OVs. Some of the shortcomings are discussed, specifically the systemic response to OVs and feasibility of treatment. Future studies can be performed in the preclinical setting to identify the ideal candidates for translation into clinical trials, as well as the nuances of this novel delivery method.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalNeurosurgical focus
Issue number2
StatePublished - Feb 2021


  • endovascular
  • glioblastoma
  • intraarterial
  • oncolytic
  • stem cell
  • virotherapy

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology


Dive into the research topics of 'Intraarterial delivery of virotherapy for glioblastoma'. Together they form a unique fingerprint.

Cite this